Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVNNYSE:CYBNNASDAQ:KURANASDAQ:VALN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$6.64-4.5%$9.04$5.94▼$37.38$484.30M2.211.28 million shs2.37 million shsCYBNCybin$6.21+2.1%$6.81$4.81▼$14.44$130.58M0.6239,684 shs135,177 shsKURAKura Oncology$5.64-2.6%$6.63$5.41▼$23.48$455.59M0.51.17 million shs1.44 million shsVALNValneva$6.59+1.7%$6.77$3.62▼$9.50$551.16M1.8536,507 shs7,798 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas-8.91%-25.83%+5.95%-64.52%-78.46%CYBNCybin-6.46%-10.72%+6.85%-38.46%+1,637.14%KURAKura Oncology-13.84%-11.20%-1.70%-36.02%-72.44%VALNValneva-1.76%+0.47%+8.36%-2.85%-13.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARVNArvinas3.1977 of 5 stars4.32.00.00.01.72.51.3CYBNCybin2.5195 of 5 stars3.50.00.00.03.20.81.3KURAKura Oncology4.0743 of 5 stars4.52.00.04.71.90.00.6VALNValneva2.4628 of 5 stars3.55.00.00.02.50.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.58Moderate Buy$20.97216.06% UpsideCYBNCybin 3.00Buy$86.001,284.86% UpsideKURAKura Oncology 2.92Moderate Buy$23.89323.56% UpsideVALNValneva 3.00Buy$16.00142.79% UpsideCurrent Analyst Ratings BreakdownLatest CYBN, ARVN, VALN, and KURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2025ARVNArvinasCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.505/5/2025ARVNArvinasBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$20.00 ➝ $10.005/5/2025ARVNArvinasTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$21.00 ➝ $11.005/2/2025ARVNArvinasBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$16.005/2/2025ARVNArvinasWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$26.00 ➝ $19.005/2/2025ARVNArvinasThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $8.005/2/2025ARVNArvinasGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $16.005/2/2025ARVNArvinasPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$24.00 ➝ $14.005/2/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$81.00 ➝ $24.005/2/2025ARVNArvinasBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$32.00 ➝ $16.005/2/2025KURAKura OncologyBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$32.00 ➝ $11.00(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$426.90M1.13N/AN/A$8.17 per share0.81CYBNCybinN/AN/AN/AN/A$10.83 per shareN/AKURAKura Oncology$67.99M6.70N/AN/A$5.35 per share1.05VALNValneva$169.58M3.25N/AN/A$2.00 per share3.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$198.90M-$0.66N/AN/AN/A-75.51%-33.75%-16.75%N/ACYBNCybin-$57.88M-$4.38N/AN/AN/AN/A-37.58%-36.59%N/AKURAKura Oncology-$152.63M-$2.10N/AN/AN/AN/A-44.09%-39.57%N/AVALNValneva-$109.78M-$0.17N/AN/AN/A-4.35%-3.93%-1.42%5/7/2025 (Estimated)Latest CYBN, ARVN, VALN, and KURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025VALNValneva-$0.40-$0.13+$0.27-$0.13$41.80 millionN/A5/1/2025Q1 2025ARVNArvinas-$0.93$1.14+$2.07$1.14$41.87 millionN/A5/1/2025Q1 2025KURAKura Oncology-$0.51-$0.66-$0.15-$0.66$39.08 million$14.11 million3/20/2025Q4 2024VALNValneva-$0.22-$0.54-$0.32-$0.54$55.64 million$56.48 million2/26/2025Q4 2024KURAKura Oncology-$0.65-$0.22+$0.43-$0.22$57.96 million$53.88 million2/11/2025Q4 2024ARVNArvinas-$1.07-$0.63+$0.44-$0.63$62.79 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/ACYBNCybinN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/AVALNValnevaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A4.644.64CYBNCybinN/A24.2424.24KURAKura Oncology0.0211.4711.47VALNValneva0.702.782.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%CYBNCybin17.94%KURAKura OncologyN/AVALNValneva11.39%Insider OwnershipCompanyInsider OwnershipARVNArvinas5.23%CYBNCybin15.00%KURAKura Oncology6.40%VALNValneva14.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42072.99 million65.18 millionOptionableCYBNCybin5021.48 million17.96 millionNot OptionableKURAKura Oncology13080.78 million73.49 millionOptionableVALNValneva70083.64 million69.15 millionNot OptionableCYBN, ARVN, VALN, and KURA HeadlinesRecent News About These CompaniesEurope reviews Valneva's chikungunya vaccine after reports of serious side effectsMay 7 at 6:22 PM | msn.comValneva dips as EU suspends use of chikungunya shot in older adultsMay 7 at 1:21 PM | msn.comValneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in ElderlyMay 7 at 11:45 AM | globenewswire.comEurope reviews Valneva's chikungunya vaccine after reports of serious side-effects in older peopleMay 7 at 8:40 AM | reuters.comValneva Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 7 at 1:00 AM | globenewswire.com7VALN : Insights Ahead: Valneva's...May 6 at 5:17 PM | benzinga.comHealth Secretary tours company's state-of-the-art manufacturing facility in LivingstonMay 5 at 11:23 AM | msn.comValneva (NASDAQ:VALN) Sees Unusually-High Trading Volume - Here's What HappenedMay 5 at 4:15 AM | marketbeat.comArvinas, Entrada cut staff; Merck builds US hub for KeytrudaMay 2, 2025 | biopharmadive.comHealth Secretary tours site of Scotland’s largest vaccine producerMay 2, 2025 | msn.comValneva (NASDAQ:VALN) Shares Down 3.6% - Here's What HappenedMay 1, 2025 | marketbeat.comValneva (VALN) Expected to Announce Earnings on TuesdayMay 1, 2025 | marketbeat.comValneva (NASDAQ:VALN) Shares Gap Down - What's Next?April 30, 2025 | marketbeat.comShort Interest in Valneva SE (NASDAQ:VALN) Drops By 49.2%April 29, 2025 | marketbeat.comValneva’s chikungunya vaccine roll-out hit by French authoritiesApril 28, 2025 | thepharmaletter.comFrance probes side effects with Valneva's chikungunya jabApril 28, 2025 | pharmaphorum.comFrench health authorities suspend use of Valneva's chikungunya vaccine in older adults to probe 3 hospitalizations, one deathApril 28, 2025 | fiercepharma.comFrance halts Valneva’s chikungunya vaccine use in seniorsApril 28, 2025 | finance.yahoo.comValneva Shares Slump After France Suspends Chikungunya Vaccine for ElderlyApril 28, 2025 | marketwatch.comIn a world first, Brazil approves chikungunya vaccineApril 28, 2025 | msn.comValneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French AuthoritiesApril 26, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYBN, ARVN, VALN, and KURA Company DescriptionsArvinas NASDAQ:ARVN$6.64 -0.32 (-4.53%) Closing price 03:59 PM EasternExtended Trading$6.80 +0.17 (+2.56%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Cybin NYSE:CYBN$6.21 +0.13 (+2.14%) Closing price 04:00 PM EasternExtended Trading$6.20 -0.01 (-0.16%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.Kura Oncology NASDAQ:KURA$5.64 -0.15 (-2.59%) Closing price 04:00 PM EasternExtended Trading$5.82 +0.18 (+3.26%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Valneva NASDAQ:VALN$6.46 -0.02 (-0.31%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
